Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Injectable Platelet-Rich Fibrin (i-PRF) and Oxygen-Releasing Gel in the Treatment of Stage II Periodontitis.

NCT: NCT07859358 · COMPLETED

NCT IDNCT07859358
StatusCOMPLETED
Start Date2026-01-20
Completion2026-07-10
SponsorAssiut University (OTHER)
First posted
Last updated

Brief Summary

Periodontitis is a chronic multifactorial inflammatory disorder affecting the periodontium, often implicated with microbial dysbiosis. Following the establishment of a proper diagnosis, the initial therapeutic phase within the recommended protocol must focus patient motivation and behavior alongside the comprehensive management of modifiable local and systemic risk factors (1). Although SRP effectively reduces microbial load, complete regeneration of periodontal tissues remains challenging due to limited healing potential and persistent inflammation. Various adjunctive therapies have been explored to enhance periodontal healing, including oxygen-based and platelet concentrate approaches (2). Topical oxygen therapy has recently gained attention for its antimicrobial and regenerative properties. Oxygen-releasing gels, such as those containing stabilized hydrogen peroxide, increase local oxygen tension, inhibit anaerobic pathogens, and promote angiogenesis and fibroblast proliferation, resulting in improved clinical parameters following SRP (3). Injectable platelet-rich fibrin (i-PRF), a second-generation autologous platelet concentrate, provides a sustained release of growth factors such as PDGF, VEGF, and TGF-β, enhancing soft tissue healing and bone regeneration. Clinical trials have demonstrated that i-PRF used with SRP significantly improves probing depth reduction, attachment gain, and bleeding scores compared with SRP alone. However, no studies have directly compared oxygen therapy and i-PRF as adjuncts to non-surgical periodontal therapy. Investigating these two bio stimulatory approaches could identify a minimally invasive, cost-effective strategy to optimize periodontal healing and regeneration.

Frequently Asked Questions

What is Injectable Platelet-Rich Fibrin (i-PRF) and Oxygen-Releasing Gel in the Treatment of Stage II Periodontitis.?

Injectable Platelet-Rich Fibrin (i-PRF) and Oxygen-Releasing Gel in the Treatment of Stage II Periodontitis. is a clinical trial registered under NCT07859358. Current status: COMPLETED.

What is the status of NCT07859358?

The current status of NCT07859358 (Injectable Platelet-Rich Fibrin (i-PRF) and Oxygen-Releasing Gel in the Treatment of Stage II Periodontitis.) is: COMPLETED.

When did Injectable Platelet-Rich Fibrin (i-PRF) and Oxygen-Releasing Gel in the Treatment of Stage II Periodontitis. start?

Injectable Platelet-Rich Fibrin (i-PRF) and Oxygen-Releasing Gel in the Treatment of Stage II Periodontitis. started on 2026-01-20.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑